查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1872307

低分子量肝素原料藥（API）－全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Low Molecular Weight Heparin API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024年全球低分子量肝素原料藥市場規模估計為 7.3億美元，預計到2031年將成長至 13.91億美元，2025年至2031年的年複合成長率為 8.0%。

本報告對近期關稅調整和國際戰略反制措施對低分子量肝素原料原料藥跨境產業佈局、資本配置模式、區域經濟相互依存關係和供應鏈重組的影響進行了全面評估。

肝素是一種抗凝血劑（血液稀釋藥物），可防止血栓形成。它用於治療和預防靜脈、動脈或肺部血栓。它也用於術前以降低血栓風險。大多數肝素產品以肝素鈉或肝素鈣的形式存在。本報告主要關注低分子量肝素原料藥（API）。

低分子量肝素（LMWH）原料藥市場在全球製藥業中扮演著舉足輕重的角色，這主要歸功於LMWH在預防和治療血栓相關疾病（例如深層靜脈栓塞症（DVT）和肺動脈栓塞（PE））方面的廣泛應用。與未分級肝素相比，LMWH活性藥物成分因其優異的藥物動力學特性（例如，生物利用度高、半衰期長、副作用風險低）而優先用於臨床應用。心血管疾病和靜脈血栓栓塞症的日益普遍、人口老化以及全球外科手術數量的不斷成長，都顯著推動了對基於LMWH治療方法的需求。

由於血栓相關疾病的高發生率和先進的醫療保健基礎設施，北美和歐洲市場推動需求，而亞太地區由於醫療費用支出增加和學名藥的興起，成為一個成長型市場。

在低分子量肝素原料藥領域，Enoxaparin Sodium佔了相當大的佔有率，預計到2030年將達到 12.5882億美元，2024年至2030年的年複合成長率為 12.46%。

全球低分子量肝素原料藥的主要企業包括煙台東城藥業、深圳海普林製藥、南京金友生化藥業、常州千虹生物製藥、青島九龍生物製藥等。截至2023年，全球前五大生產商的收入佔有率將佔全球總收入的約72.91%。

本報告目的是對全球低分子量肝素原料藥市場依地區/國家、類型和應用進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

低分子量肝素原料藥市場規模、估算和預測以銷售量（十億）和收入（百萬美元）為單位呈現，基準年為2024年，並包含2020年至2031年期間的歷史資料和預測資料。定量和定性分析相結合，有助於讀者制定業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並就低分子量肝素原料藥做出明智的商業決策。

市場區隔

公司

  • Yantai Dongcheng Pharmaceutical
  • Shenzhen Hepalink Pharmaceutical
  • Nanjing King-friend
  • Changzhou Qianhong Biopharma
  • Qingdao Jiulong Biopharmaceutical
  • Dongying Tiandong Pharmaceutical
  • Yino Pharma
  • Opocrin
  • Hebei Changshan
  • Hubei Enoray Biopharmaceutical
  • Nanjing Nanda Pharmaceutical
  • Cisen Pharmaceutical

依類型

  • 低分子量肝素鈉
  • 低分子量肝素鈣

依應用

  • Enoxaparin Sodium
  • Nadroparin Calcium
  • Dalteparin Sodium
  • Tinzaparin Sodium
  • Parnaparin Sodium

依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Low Molecular Weight Heparin API was estimated to be worth US$ 730 million in 2024 and is forecast to a readjusted size of US$ 1391 million by 2031 with a CAGR of 8.0% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Low Molecular Weight Heparin API cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium. In this report, we mainly study the low molecular weight heparin API.

The Low Molecular Weight Heparin (LMWH) API market plays a crucial role in the global pharmaceutical industry due to the widespread use of LMWHs in the prevention and treatment of blood clot-related disorders, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). LMWH APIs are preferred in clinical settings for their favorable pharmacological properties, including better bioavailability, longer half-life, and reduced risk of side effects compared to unfractionated heparin. The increasing prevalence of cardiovascular diseases and venous thromboembolism, aging populations, and a rise in surgical procedures worldwide have significantly driven demand for LMWH-based therapies.

The North American and European markets lead in demand due to a high prevalence of thrombosis-related conditions and advanced healthcare infrastructure. Asia-Pacific is emerging as a growth market, driven by increased healthcare spending and the rise of generics.

Low Molecular Weight Heparin API segment market, the Enoxaparin Sodium holds an important share, and it is expected to reach a value of US$ 1,258.82 million by 2030, at a CAGR of 12.46% during 2024 and 2030.

The global key companies of Low Molecular Weight Heparin API include Yantai Dongcheng Pharmaceutical, Shenzhen Hepalink Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Changzhou Qianhong Biopharma, and Qingdao Jiulong Biopharmaceutical, etc. In 2023, the global five largest players hold a share approximately 72.91% in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Low Molecular Weight Heparin API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Low Molecular Weight Heparin API by region & country, by Type, and by Application.

The Low Molecular Weight Heparin API market size, estimations, and forecasts are provided in terms of sales volume (Billion Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Low Molecular Weight Heparin API.

Market Segmentation

By Company

  • Yantai Dongcheng Pharmaceutical
  • Shenzhen Hepalink Pharmaceutical
  • Nanjing King-friend
  • Changzhou Qianhong Biopharma
  • Qingdao Jiulong Biopharmaceutical
  • Dongying Tiandong Pharmaceutical
  • Yino Pharma
  • Opocrin
  • Hebei Changshan
  • Hubei Enoray Biopharmaceutical
  • Nanjing Nanda Pharmaceutical
  • Cisen Pharmaceutical

Segment by Type

  • Low Molecular Weight Heparin Sodium
  • Low Molecular Weight Heparin Calcium

Segment by Application

  • Enoxaparin Sodium
  • Nadroparin Calcium
  • Dalteparin Sodium
  • Tinzaparin Sodium
  • Parnaparin Sodium

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Low Molecular Weight Heparin API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Low Molecular Weight Heparin API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Low Molecular Weight Heparin API in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Low Molecular Weight Heparin API Product Introduction
  • 1.2 Global Low Molecular Weight Heparin API Market Size Forecast
    • 1.2.1 Global Low Molecular Weight Heparin API Sales Value (2020-2031)
    • 1.2.2 Global Low Molecular Weight Heparin API Sales Volume (2020-2031)
    • 1.2.3 Global Low Molecular Weight Heparin API Sales Price (2020-2031)
  • 1.3 Low Molecular Weight Heparin API Market Trends & Drivers
    • 1.3.1 Low Molecular Weight Heparin API Industry Trends
    • 1.3.2 Low Molecular Weight Heparin API Market Drivers & Opportunity
    • 1.3.3 Low Molecular Weight Heparin API Market Challenges
    • 1.3.4 Low Molecular Weight Heparin API Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Low Molecular Weight Heparin API Players Revenue Ranking (2024)
  • 2.2 Global Low Molecular Weight Heparin API Revenue by Company (2020-2025)
  • 2.3 Global Low Molecular Weight Heparin API Players Sales Volume Ranking (2024)
  • 2.4 Global Low Molecular Weight Heparin API Sales Volume by Company Players (2020-2025)
  • 2.5 Global Low Molecular Weight Heparin API Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Low Molecular Weight Heparin API Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Low Molecular Weight Heparin API Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Low Molecular Weight Heparin API
  • 2.9 Low Molecular Weight Heparin API Market Competitive Analysis
    • 2.9.1 Low Molecular Weight Heparin API Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Low Molecular Weight Heparin API Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Low Molecular Weight Heparin API as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Low Molecular Weight Heparin Sodium
    • 3.1.2 Low Molecular Weight Heparin Calcium
  • 3.2 Global Low Molecular Weight Heparin API Sales Value by Type
    • 3.2.1 Global Low Molecular Weight Heparin API Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Low Molecular Weight Heparin API Sales Value, by Type (2020-2031)
    • 3.2.3 Global Low Molecular Weight Heparin API Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Low Molecular Weight Heparin API Sales Volume by Type
    • 3.3.1 Global Low Molecular Weight Heparin API Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Low Molecular Weight Heparin API Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Low Molecular Weight Heparin API Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Low Molecular Weight Heparin API Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Enoxaparin Sodium
    • 4.1.2 Nadroparin Calcium
    • 4.1.3 Dalteparin Sodium
    • 4.1.4 Tinzaparin Sodium
    • 4.1.5 Parnaparin Sodium
  • 4.2 Global Low Molecular Weight Heparin API Sales Value by Application
    • 4.2.1 Global Low Molecular Weight Heparin API Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Low Molecular Weight Heparin API Sales Value, by Application (2020-2031)
    • 4.2.3 Global Low Molecular Weight Heparin API Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Low Molecular Weight Heparin API Sales Volume by Application
    • 4.3.1 Global Low Molecular Weight Heparin API Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Low Molecular Weight Heparin API Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Low Molecular Weight Heparin API Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Low Molecular Weight Heparin API Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Low Molecular Weight Heparin API Sales Value by Region
    • 5.1.1 Global Low Molecular Weight Heparin API Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Low Molecular Weight Heparin API Sales Value by Region (2020-2025)
    • 5.1.3 Global Low Molecular Weight Heparin API Sales Value by Region (2026-2031)
    • 5.1.4 Global Low Molecular Weight Heparin API Sales Value by Region (%), (2020-2031)
  • 5.2 Global Low Molecular Weight Heparin API Sales Volume by Region
    • 5.2.1 Global Low Molecular Weight Heparin API Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Low Molecular Weight Heparin API Sales Volume by Region (2020-2025)
    • 5.2.3 Global Low Molecular Weight Heparin API Sales Volume by Region (2026-2031)
    • 5.2.4 Global Low Molecular Weight Heparin API Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Low Molecular Weight Heparin API Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 5.4.2 North America Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 5.5.2 Europe Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Low Molecular Weight Heparin API Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 5.7.2 South America Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Low Molecular Weight Heparin API Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Low Molecular Weight Heparin API Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Low Molecular Weight Heparin API Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.3.2 United States Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.4.2 Europe Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.5.2 China Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.6.2 Japan Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.7.2 South Korea Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.9.2 India Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Yantai Dongcheng Pharmaceutical
    • 7.1.1 Yantai Dongcheng Pharmaceutical Company Information
    • 7.1.2 Yantai Dongcheng Pharmaceutical Introduction and Business Overview
    • 7.1.3 Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.1.5 Yantai Dongcheng Pharmaceutical Recent Development
  • 7.2 Shenzhen Hepalink Pharmaceutical
    • 7.2.1 Shenzhen Hepalink Pharmaceutical Company Information
    • 7.2.2 Shenzhen Hepalink Pharmaceutical Introduction and Business Overview
    • 7.2.3 Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.2.5 Shenzhen Hepalink Pharmaceutical Recent Development
  • 7.3 Nanjing King-friend
    • 7.3.1 Nanjing King-friend Company Information
    • 7.3.2 Nanjing King-friend Introduction and Business Overview
    • 7.3.3 Nanjing King-friend Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Nanjing King-friend Low Molecular Weight Heparin API Product Offerings
    • 7.3.5 Nanjing King-friend Recent Development
  • 7.4 Changzhou Qianhong Biopharma
    • 7.4.1 Changzhou Qianhong Biopharma Company Information
    • 7.4.2 Changzhou Qianhong Biopharma Introduction and Business Overview
    • 7.4.3 Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Product Offerings
    • 7.4.5 Changzhou Qianhong Biopharma Recent Development
  • 7.5 Qingdao Jiulong Biopharmaceutical
    • 7.5.1 Qingdao Jiulong Biopharmaceutical Company Information
    • 7.5.2 Qingdao Jiulong Biopharmaceutical Introduction and Business Overview
    • 7.5.3 Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.5.5 Qingdao Jiulong Biopharmaceutical Recent Development
  • 7.6 Dongying Tiandong Pharmaceutical
    • 7.6.1 Dongying Tiandong Pharmaceutical Company Information
    • 7.6.2 Dongying Tiandong Pharmaceutical Introduction and Business Overview
    • 7.6.3 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.6.5 Dongying Tiandong Pharmaceutical Recent Development
  • 7.7 Yino Pharma
    • 7.7.1 Yino Pharma Company Information
    • 7.7.2 Yino Pharma Introduction and Business Overview
    • 7.7.3 Yino Pharma Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Yino Pharma Low Molecular Weight Heparin API Product Offerings
    • 7.7.5 Yino Pharma Recent Development
  • 7.8 Opocrin
    • 7.8.1 Opocrin Company Information
    • 7.8.2 Opocrin Introduction and Business Overview
    • 7.8.3 Opocrin Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Opocrin Low Molecular Weight Heparin API Product Offerings
    • 7.8.5 Opocrin Recent Development
  • 7.9 Hebei Changshan
    • 7.9.1 Hebei Changshan Company Information
    • 7.9.2 Hebei Changshan Introduction and Business Overview
    • 7.9.3 Hebei Changshan Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Hebei Changshan Low Molecular Weight Heparin API Product Offerings
    • 7.9.5 Hebei Changshan Recent Development
  • 7.10 Hubei Enoray Biopharmaceutical
    • 7.10.1 Hubei Enoray Biopharmaceutical Company Information
    • 7.10.2 Hubei Enoray Biopharmaceutical Introduction and Business Overview
    • 7.10.3 Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.10.5 Hubei Enoray Biopharmaceutical Recent Development
  • 7.11 Nanjing Nanda Pharmaceutical
    • 7.11.1 Nanjing Nanda Pharmaceutical Company Information
    • 7.11.2 Nanjing Nanda Pharmaceutical Introduction and Business Overview
    • 7.11.3 Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.11.5 Nanjing Nanda Pharmaceutical Recent Development
  • 7.12 Cisen Pharmaceutical
    • 7.12.1 Cisen Pharmaceutical Company Information
    • 7.12.2 Cisen Pharmaceutical Introduction and Business Overview
    • 7.12.3 Cisen Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 Cisen Pharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.12.5 Cisen Pharmaceutical Recent Development

8 Industry Chain Analysis

  • 8.1 Low Molecular Weight Heparin API Industrial Chain
  • 8.2 Low Molecular Weight Heparin API Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Low Molecular Weight Heparin API Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Low Molecular Weight Heparin API Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Low Molecular Weight Heparin API Market Trends
  • Table 2. Low Molecular Weight Heparin API Market Drivers & Opportunity
  • Table 3. Low Molecular Weight Heparin API Market Challenges
  • Table 4. Low Molecular Weight Heparin API Market Restraints
  • Table 5. Global Low Molecular Weight Heparin API Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Low Molecular Weight Heparin API Revenue Market Share by Company (2020-2025)
  • Table 7. Global Low Molecular Weight Heparin API Sales Volume by Company (2020-2025) & (Billion Units)
  • Table 8. Global Low Molecular Weight Heparin API Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Low Molecular Weight Heparin API Price by Company (2020-2025) & (US$/Billion Untis)
  • Table 10. Key Manufacturers Low Molecular Weight Heparin API Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Low Molecular Weight Heparin API Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Low Molecular Weight Heparin API
  • Table 13. Global Low Molecular Weight Heparin API Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Low Molecular Weight Heparin API as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Low Molecular Weight Heparin API Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Low Molecular Weight Heparin API Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Low Molecular Weight Heparin API Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Low Molecular Weight Heparin API Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Low Molecular Weight Heparin API Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Low Molecular Weight Heparin API Sales Volume by Type: 2020 VS 2024 VS 2031 (Billion Units)
  • Table 22. Global Low Molecular Weight Heparin API Sales Volume by Type (2020-2025) & (Billion Units)
  • Table 23. Global Low Molecular Weight Heparin API Sales Volume by Type (2026-2031) & (Billion Units)
  • Table 24. Global Low Molecular Weight Heparin API Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Low Molecular Weight Heparin API Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Low Molecular Weight Heparin API Price by Type (2020-2025) & (US$/Billion Untis)
  • Table 27. Global Low Molecular Weight Heparin API Price by Type (2026-2031) & (US$/Billion Untis)
  • Table 28. Global Low Molecular Weight Heparin API Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Low Molecular Weight Heparin API Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Low Molecular Weight Heparin API Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Low Molecular Weight Heparin API Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Low Molecular Weight Heparin API Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Low Molecular Weight Heparin API Sales Volume by Application: 2020 VS 2024 VS 2031 (Billion Units)
  • Table 34. Global Low Molecular Weight Heparin API Sales Volume by Application (2020-2025) & (Billion Units)
  • Table 35. Global Low Molecular Weight Heparin API Sales Volume by Application (2026-2031) & (Billion Units)
  • Table 36. Global Low Molecular Weight Heparin API Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Low Molecular Weight Heparin API Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Low Molecular Weight Heparin API Price by Application (2020-2025) & (US$/Billion Untis)
  • Table 39. Global Low Molecular Weight Heparin API Price by Application (2026-2031) & (US$/Billion Untis)
  • Table 40. Global Low Molecular Weight Heparin API Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Low Molecular Weight Heparin API Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Low Molecular Weight Heparin API Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Low Molecular Weight Heparin API Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Low Molecular Weight Heparin API Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Low Molecular Weight Heparin API Sales Volume by Region (Billion Units): 2020 VS 2024 VS 2031
  • Table 46. Global Low Molecular Weight Heparin API Sales Volume by Region (2020-2025) & (Billion Units)
  • Table 47. Global Low Molecular Weight Heparin API Sales Volume by Region (2026-2031) & (Billion Units)
  • Table 48. Global Low Molecular Weight Heparin API Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Low Molecular Weight Heparin API Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Low Molecular Weight Heparin API Average Price by Region (2020-2025) & (US$/Billion Untis)
  • Table 51. Global Low Molecular Weight Heparin API Average Price by Region (2026-2031) & (US$/Billion Untis)
  • Table 52. Key Countries/Regions Low Molecular Weight Heparin API Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Low Molecular Weight Heparin API Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Low Molecular Weight Heparin API Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Low Molecular Weight Heparin API Sales Volume, (2020-2025) & (Billion Units)
  • Table 56. Key Countries/Regions Low Molecular Weight Heparin API Sales Volume, (2026-2031) & (Billion Units)
  • Table 57. Yantai Dongcheng Pharmaceutical Company Information
  • Table 58. Yantai Dongcheng Pharmaceutical Introduction and Business Overview
  • Table 59. Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 60. Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 61. Yantai Dongcheng Pharmaceutical Recent Development
  • Table 62. Shenzhen Hepalink Pharmaceutical Company Information
  • Table 63. Shenzhen Hepalink Pharmaceutical Introduction and Business Overview
  • Table 64. Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 65. Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 66. Shenzhen Hepalink Pharmaceutical Recent Development
  • Table 67. Nanjing King-friend Company Information
  • Table 68. Nanjing King-friend Introduction and Business Overview
  • Table 69. Nanjing King-friend Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 70. Nanjing King-friend Low Molecular Weight Heparin API Product Offerings
  • Table 71. Nanjing King-friend Recent Development
  • Table 72. Changzhou Qianhong Biopharma Company Information
  • Table 73. Changzhou Qianhong Biopharma Introduction and Business Overview
  • Table 74. Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 75. Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Product Offerings
  • Table 76. Changzhou Qianhong Biopharma Recent Development
  • Table 77. Qingdao Jiulong Biopharmaceutical Company Information
  • Table 78. Qingdao Jiulong Biopharmaceutical Introduction and Business Overview
  • Table 79. Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 80. Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 81. Qingdao Jiulong Biopharmaceutical Recent Development
  • Table 82. Dongying Tiandong Pharmaceutical Company Information
  • Table 83. Dongying Tiandong Pharmaceutical Introduction and Business Overview
  • Table 84. Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 85. Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 86. Dongying Tiandong Pharmaceutical Recent Development
  • Table 87. Yino Pharma Company Information
  • Table 88. Yino Pharma Introduction and Business Overview
  • Table 89. Yino Pharma Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 90. Yino Pharma Low Molecular Weight Heparin API Product Offerings
  • Table 91. Yino Pharma Recent Development
  • Table 92. Opocrin Company Information
  • Table 93. Opocrin Introduction and Business Overview
  • Table 94. Opocrin Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 95. Opocrin Low Molecular Weight Heparin API Product Offerings
  • Table 96. Opocrin Recent Development
  • Table 97. Hebei Changshan Company Information
  • Table 98. Hebei Changshan Introduction and Business Overview
  • Table 99. Hebei Changshan Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 100. Hebei Changshan Low Molecular Weight Heparin API Product Offerings
  • Table 101. Hebei Changshan Recent Development
  • Table 102. Hubei Enoray Biopharmaceutical Company Information
  • Table 103. Hubei Enoray Biopharmaceutical Introduction and Business Overview
  • Table 104. Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 105. Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 106. Hubei Enoray Biopharmaceutical Recent Development
  • Table 107. Nanjing Nanda Pharmaceutical Company Information
  • Table 108. Nanjing Nanda Pharmaceutical Introduction and Business Overview
  • Table 109. Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 110. Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 111. Nanjing Nanda Pharmaceutical Recent Development
  • Table 112. Cisen Pharmaceutical Company Information
  • Table 113. Cisen Pharmaceutical Introduction and Business Overview
  • Table 114. Cisen Pharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 115. Cisen Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 116. Cisen Pharmaceutical Recent Development
  • Table 117. Key Raw Materials Lists
  • Table 118. Raw Materials Key Suppliers Lists
  • Table 119. Low Molecular Weight Heparin API Downstream Customers
  • Table 120. Low Molecular Weight Heparin API Distributors List
  • Table 121. Research Programs/Design for This Report
  • Table 122. Key Data Information from Secondary Sources
  • Table 123. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Low Molecular Weight Heparin API Product Picture
  • Figure 2. Global Low Molecular Weight Heparin API Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Low Molecular Weight Heparin API Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Low Molecular Weight Heparin API Sales Volume (2020-2031) & (Billion Units)
  • Figure 5. Global Low Molecular Weight Heparin API Sales Price (2020-2031) & (US$/Billion Untis)
  • Figure 6. Low Molecular Weight Heparin API Report Years Considered
  • Figure 7. Global Low Molecular Weight Heparin API Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Low Molecular Weight Heparin API Players Sales Volume Ranking (2024) & (Billion Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Low Molecular Weight Heparin API Revenue in 2024
  • Figure 10. Low Molecular Weight Heparin API Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Low Molecular Weight Heparin Sodium Picture
  • Figure 12. Low Molecular Weight Heparin Calcium Picture
  • Figure 13. Global Low Molecular Weight Heparin API Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Low Molecular Weight Heparin API Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global Low Molecular Weight Heparin API Sales Volume by Type (2020 VS 2024 VS 2031) & (Billion Units)
  • Figure 16. Global Low Molecular Weight Heparin API Sales Volume Market Share by Type, 2024 & 2031
  • Figure 17. Global Low Molecular Weight Heparin API Price by Type (2020-2031) & (US$/Billion Untis)
  • Figure 18. Product Picture of Enoxaparin Sodium
  • Figure 19. Product Picture of Nadroparin Calcium
  • Figure 20. Product Picture of Dalteparin Sodium
  • Figure 21. Product Picture of Tinzaparin Sodium
  • Figure 22. Product Picture of Parnaparin Sodium
  • Figure 23. Global Low Molecular Weight Heparin API Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 24. Global Low Molecular Weight Heparin API Sales Value Market Share by Application, 2024 & 2031
  • Figure 25. Global Low Molecular Weight Heparin API Sales Volume by Application (2020 VS 2024 VS 2031) & (Billion Units)
  • Figure 26. Global Low Molecular Weight Heparin API Sales Volume Market Share by Application, 2024 & 2031
  • Figure 27. Global Low Molecular Weight Heparin API Price by Application (2020-2031) & (US$/Billion Untis)
  • Figure 28. North America Low Molecular Weight Heparin API Sales Value (2020-2031) & (US$ Million)
  • Figure 29. North America Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Europe Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Europe Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • Figure 32. Asia Pacific Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Asia Pacific Low Molecular Weight Heparin API Sales Value by Region (%), 2024 VS 2031
  • Figure 34. South America Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. South America Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • Figure 36. Middle East & Africa Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Middle East & Africa Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • Figure 38. Key Countries/Regions Low Molecular Weight Heparin API Sales Value (%), (2020-2031)
  • Figure 39. Key Countries/Regions Low Molecular Weight Heparin API Sales Volume (%), (2020-2031)
  • Figure 40. United States Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. United States Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 42. United States Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 43. Europe Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. Europe Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 45. Europe Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 46. China Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. China Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 48. China Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 49. Japan Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. Japan Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 51. Japan Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 52. South Korea Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 53. South Korea Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 54. South Korea Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 55. Southeast Asia Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 56. Southeast Asia Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 57. Southeast Asia Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 58. India Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 59. India Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 60. India Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 61. Low Molecular Weight Heparin API Industrial Chain
  • Figure 62. Low Molecular Weight Heparin API Manufacturing Cost Structure
  • Figure 63. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 64. Bottom-up and Top-down Approaches for This Report
  • Figure 65. Data Triangulation
  • Figure 66. Key Executives Interviewed